For the Inventor, By the Inventor

Enter assignee name

Doylestown, PA, United States of America

Novira Therapeutics, Inc.

USPTO Granted Patents = 44

CIPO Patents = 1

EPO Patents = 8

Forward Citations = 437

Loading Chart...

Loading Chart...

13 inventors (with patents filed for the assignee):

George D Hartman (38 out of 183 patents)

Scott D Kuduk (20 out of 118 patents)

Osvaldo A Flores (8 out of 13 patents)

4. Nicholas Simon Stock (6 out of 37 patents)

5. Ryan Christopher Clark (6 out of 18 patents)

6. Jason Duarte Jacintho (6 out of 12 patents)

7. Bijan Pedram (3 out of 18 patents)

8. Austin Chen (3 out of 10 patents)

9. Yen Truong (3 out of 17 patents)

10. Yalda Mostofi Bravo (3 out of 19 patents)

11. Man Iu Lam (2 out of 2 patents)

12. Jan Martin Berke (2 out of 5 patents)

13. Klaus G Klumpp (2 out of 12 patents)

14. Christine Lisa Espiritu (0 patent)

15. Jason Jacintho (0 patent)

Core Competencies:

Hepatitis B

Antiviral Agents

Capsid Assembly Inhibitor

Oxadiazepinone Derivatives

Sulfide Alkyl Compounds

Combination Therapy

Pyridyl Reverse Sulfonamides

Azepane Derivatives

Azocane Derivatives

Crystalline Forms

Diazepinone Derivatives

Derivatives Treatment

44 patents: Sort by Forward Citations

1. 11129834 - Combinations and methods comprising a capsid assembly inhibitor (2021-09-28),

2. 10987359 - Oxadiazepinone derivatives and methods of treating hepatitis B infections (2021-04-27),

3. 10975077 - Diazepinone derivatives and their use in the treatment of hepatitis B infections (2021-04-13),

4. 10710959 - Sulfide alkyl compounds for HBV treatment (2020-07-14),

5. 10632112 - Combination therapy for treatment of HBV infections (2020-04-28),

6. 10556904 - Derivatives and methods of treating hepatitis B infections (2020-02-11),

7. 10544141 - Derivatives and methods of treating hepatitis B infections (2020-01-28),

8. 10538519 - Derivatives and methods of treating hepatitis B infections (2020-01-21),

9. 10537580 - Azocane and azonane derivatives and methods of treating hepatitis B infections (2020-01-21),

10. 10441589 - Combinations and methods comprising a capsid assembly inhibitor (2019-10-15),

11. 10428041 - Pyridyl reverse sulfonamides for HBV treatment (2019-10-01),

12. 10392349 - Azepane derivatives and methods of treating hepatitis B infections (2019-08-27),

13. 10364228 - Azepane derivatives and methods of treating hepatitis B infections (2019-07-30),

14. 10213420 - Combination therapy for treatment of HBV infections (2019-02-26),

15. 10196376 - Hepatitis B antiviral agents (2019-02-05),

Novira Therapeutics, Inc. is a pharmaceutical company focused on the development of innovative antiviral therapies. They specialize in the research and treatment of viral infections, particularly those affecting the liver. With a dedicated team of scientists and clinicians, Novira Therapeutics is committed to advancing patient care and improving treatment outcomes. Visit their website to learn more about their groundbreaking research and ongoing clinical trials.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

44 Patents

#1 in Doylestown, PA

#291 in Pennsylvania

#7,674 in US

#15,297 in the World

Doylestown, PA, United States of America

Novira Therapeutics, Inc.

Forward Citations = 437

13 inventors:

George D Hartman (38 out of 183 patents)

Scott D Kuduk (20 out of 118 patents)

Osvaldo A Flores (8 out of 13 patents)

4. Nicholas Simon Stock (6 out of 37 patents)

5. Ryan Christopher Clark (6 out of 18 patents)

Please report any incorrect information to support@idiyas.com

Loading…